ArticlePsychopharmacology2026
Endocannabinoid response to social stress in chronic non-medical prescription opioid users.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EBPS2023 special issue: Stress, trauma and cannabinoids.Psychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe ongoing global opioid crisis underscores the need to better understand the neurobiological mechanisms underlying opioid use disorder (OUD). Stress is a key risk factor for developing and maintaining OUD. While animal models report that the endocannabinoid system (ECS) plays a modulatory role in stress response, alterations of ECS stress reactivity in individuals with OUD have yet to be studied.
objectivesHere, we aimed to study the response of the ECS to experimentally-induced mild psychosocial stress in individuals with non-medical prescription opioid use (NMPOU) without intravenous use.
methodsWe compared plasma concentrations of the two main endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (AEA) along with structurally related N-acylethalonamines (NAEs) and arachidonic acid (AA) between individuals with chronic NMPOU (n = 21) and matched opioid-naïve healthy controls (n = 29) after social exclusion using the Cyberball task. Blood samples were collected before stress induction, and 10, 20, 30, and 60 min after stress onset.
resultsWe found a significant GROUP*TIME interaction for 2-AG, with controls showing increased 2-AG plasma levels after stress, contrasting with a blunted stress response in NMPOU. Both groups robustly differed in 2-AG levels at all time points after stress induction. No significant GROUP*TIME interactions were found for AEA, NAEs, and AA. Increased 2-AG levels were associated with greater feelings of social inclusion overall.
conclusionResults suggest dysfunctional stress response at the level of the ECS in individuals with NMPOU. Specifically 2-AG might play a critical role in stress resilience and, thus, it might be a potential pharmacotherapeutic target in the treatment of OUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.